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Abstract
Background: Microvolt T-wave alternans (MTWA) is a promising method for noninvasive
assessment of arrhythmic risk. Recent studies have shown good immediate reproducibility of
T-wave alternans. Little is known about it during the long term. The aim of the study was to
prospectively evaluate the long-term reproducibility of MTWA in a group of patients after ICD
implantation.
Methods: The study group consisted of 22 patients: 21 male and 1 female, aged 63.0 ± 7.6 years.
Nineteen of them had a history of myocardial infarction and 3 had non-ischemic cardiomyopa-
thy. Ejection fraction was 34.7 ± 10.0. T-wave alternans was measured during treadmill tests
and additionally in 6 patients during implantation cardioverter-defibrillator device pacing.
We received 30 reports of MTWA available for analysis. The second test was performed after
11.8 ± 3.3 months (range 7–16) using the same protocol.
Results: Of the 30 tests, 12 were positive, 2 negative and 9 indeterminate in both tests. The
results were concordant in 23 tests (76.66%) (Kappa 0.602). Of the initial positive tests, only
one became negative in the second test and 4 became indeterminate. Of the initial negative
tests, none became positive and none became indeterminate. Of the initial indeterminate tests,
one became positive and one negative. At the same time, there were no significant differences
between QRS, QTc and ejection fraction between the first and second tests. Only the heart rate
in the second test was greater than in the first.
Conclusions: The results suggest that microvolt T-wave alternans measurement is stable
over a long period. It is probably not worth examining the status of MTWA after several months,
at least if patients are in the chronic stage of their disease. (Cardiol J 2007; 14: 561–567)
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Introduction
T-wave alternans (TWA) is an electrocardio-
graphic pattern in which the morphology of the
T-wave alternates on an ‘every-other beat’ basis.
Visible alternans in the electrocardiogram is a rare
finding associated with the variety of pathophysio-
logical conditions which are in turn associated with
increased risk of ventricular arrhythmias such as
acute ischaemia, Prinzmetal’s angina, electrolyte
abnormalities and long QT syndrome [1–6]. Thanks
to advancement in signal processing methods, it has
become possible to measure microvolt T-wave al-
ternans (MTWA) which cannot be detected by vis-
ual inspection of the electrocardiogram [7]. Elec-
trophysiological mapping studies have demonstrat-
ed that TWA is caused by localized alternation in
the duration of the action potential. Localized
action potential alternans leads, in turn, to spatial
dispersion of recovery leading to the fractionation
of depolarization wave fronts and the development
of re-entrant arrhythmias — ventricular tachycardia
and fibrillation [8–10].
A number of excellent studies have shown that
TWA is an effective noninvasive predictor of risk
of ventricular tachyarrhythmias and sudden death,
with an efficacy that appears at least comparable to
invasive electrophysiological testing [11–14]. The
latest recommendations, according to ACC/AHA/
/ESC 2006 Guidelines for Management of Patients
With Ventricular Arrhythmias and the Prevention
of Sudden Cardiac Death class IIa with level of ev-
idence A, pointed out that ‘it is reasonable to use
TWA to improve the diagnosis and risk stratifica-
tion of patients with ventricular arrhythmias or who
are at risk for developing life threatening ventricu-
lar arrhythmias’ [15].
Many other studies have shown different meth-
odological aspects of TWA measurement. Hohnlos-
er et al. [16] have shown the equivalence of meas-
urement during atrial pacing and bicycle exercise.
Others try to resolve questions concerning how to
measure TWA when the QRS complex is altered due
to bundle brunch block or ventricular pacing [17–20].
Another important question concerns the appropri-
ate time for TWA evaluation after acute myocardial
infarction. Hohnloser et al. [21] found that T-wave
alternans evolved substantially between 5 and
21 days and from 28 to 56 days after myocardial in-
farction. The concordance rate between determi-
nate TWA in the two periods was only 67%. Tapa-
nainen et al. [22] studied 379 patients with a mean
period of 8.1 days after myocardial infarction and did
not find a statistically significant elevation of cardiac
deaths among patients who tested positive for TWA.
These studies showed that T-wave alternans
evolves rapidly during the acute post-infarction
period and it is now suggested that TWA be meas-
ured not earlier than 6 weeks after myocardial
infarction.
There are only a few papers assessing the re-
producibility of TWA, showing the dilemma of
whether this localized action potential alternans is
stable over time. Bloomfield et al. [23] has shown
that TWA measured during bicycle exercise tests
had an acceptable reproducibility when measure-
ments were made during two sequential exercise
tests performed within a short period of time (one
after another) and additionally, that repeating the
test could significantly reduce the proportion of pa-
tients with indeterminate test results. Until now
only Klingenheben et al. [24] have evaluated the
long-term reproducibility of TWA in a group of pa-
tients after myocardial infarction.
The aim of this prospective study was to eval-
uate the long-term reproducibility in a group of pa-
tients who underwent the cardioverter defibrillator
implantation (ICD).
Methods
The study group consisted of 22 patients who
are participating in our own prospective program
of evaluating risk factors in secondary and primary
prevention after ICD implantation. There were
21 men and 1 woman. Nineteen of them had a history
of myocardial infarction and 3 had non-ischaemic
cardiomyopathy. The clinical characteristics of the
study group are shown in Table 1.
The algorithm of evaluating T-wave alternans
based on the spectral method was described previ-
ously [25]. In brief, the analysis is based on the
measurement of the differences between odd and
even cycles in a sequence of 128 beats, applying
a fast Fourier transform. Tests were classified as
positive, negative or indeterminate [26]. We classi-
fied alternans as positive when the onset heart rate
(HR), the specific heart rate above which sustained
alternans is present, was less than 110 beats/min.
A negative test was when the criteria for positive
were not fulfilled and when maximal negative heart
rate was ≥ 105 beats/min. The indeterminate test
was when we could not classify it as positive or
negative. The details of classification are described
in the references [25, 26]. After careful skin prepa-
ration, microvolt T-wave alternans was measured
during treadmill tests. If the test was indeterminate,
it was immediately repeated. Additionally, 6 of the
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patients with indeterminate tests due to the insuf-
ficient heart rate had atrial or/and atrioventricular
pacing using an ICD device to reach it. According
to the measurement protocol, to obtain the neces-
sary heart rate we increased the pacing heart rate
every 10 beats for at least 1 minute starting from
70/beats/min up to 110/beats/min. We evaluated
MTWA using the commercially available Cambridge
Heart 2000 System.
The second test was performed after 11.8 ±
± 3.3 months, range 7–16 months, according to
the same protocol. Finally, we received 30 reports
of MTWA which could be compared: those per-
formed on the treadmill with each other and those
performed during ICD stimulation with each oth-
er, respectively. Standard ECG with evaluation
of HR, QRS complex and corrected QT interval
and echocardiography with evaluation of  ejection
fraction (EF) were performed before each MTWA
test for all of the patients. All patients had re-
ceived beta-blockers and the treatment had not
been discontinued before the tests. All of them
where screened every three months for ICD dis-
charge.
We obtained local ethics committee agreement,
and all patients had agreed to participate in the
study.
Statistical analysis
The main analysis of the data was created to
establish the long-term reproducibility of T-wave
alternans. We have obtained 2 kinds of results
— determinate (positive or negative) and indeter-
minate, so we analyzed all the results together as
well as determinate results separately.
The reproducibility of the results was deter-
mined by a statistical measure of agreement called
the Kappa statistic. A Kappa statistic between
0.4 and 0.7 means good, above 0.7 is excellent and
less than 0.4 is a poor agreement of results. The
clinical data were analyzed by Wilcoxon paired test.
Results
Of the 30 tests, 12 were positive, 2 were neg-
ative and 9 were indeterminate in both tests. The
results were concordant in 23 tests (76.66%)
(Kappa 0.602). For determinate tests the reproduci-
bility was 73.6%. Examples of the reproducibility of
the results of MTWA are shown in Figures 1 and 2.
Of the initial positive tests, only one became neg-
ative in the second test and four became indeterminate.
Of the initial negative testsn none became positive and
none became indeterminate. Of the initial indeter-
minate tests, one became positive and one negative.
The reproducibility of MTWA is shown in Table 2.
At the same time, there were no statistical dif-
ferences between onset HR of MTWA in the first
and second tests in the group of both positive tests.
There were no differences between supine ECG
parameters such as QRS or QTc and between the
EF before the first and second tests. Only the su-
pine heart rate before the second test was greater
than the first: 62.96 ± 8.84 vs. 65.58 ± 12.39 beats/
/min (p = 0.024). At same time, there were no dif-
ferences in onset HR between the two tests. The
results are shown in Table 3.
During this prospective observation, 11 of
22 patients had appropriate ICD discharge. In this
group, 5 had both tests positive, 2 had the first test
positive and second indeterminate, 2 had both tests
indeterminate and 1 had the first test positive
whereas the second was negative. Only 1 patient
with negative first and second test had the appro-
priate discharge.
Discussion
The study showed good reproducibility (76.6%)
of all the results (Kappa 0.602). This is the first
study which has shown the long-term reproducibil-
ity of MTWA in a group of patients in the stable
Table 1. Clinical characteristics of the patients.
Patients (male) 22 (21)
Age 63.0 ± 7.6
Ejection fraction (%) 34.7 ± 10.0
Etiology:
Ischemic 19
Cardiomyopathy 3
Reason for cardioverter-defibrillator
implantation:
History SCD (reversible) 9
History of sustained ventricular 10
tachycardia
Electrophysiological study 1
(positive) + low EF (< 35%)
Sudden cardiac death 1
of unknown reason
Syncope of unknown 1
reason + low EF
Low EF + no sustained ventricular 1
tachycardia in Holter monitoring
Medication:
Beta-blocker (first/second test) 22/22
Amiodarone (first/second test) 10/8
SCD — sudden cardiac death; EF — ejection fraction
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Figure 1. Reproducibility of microvolt T-wave alternans (MTWA) in precordial leads (V1, V2, V3, V4, V5, V6); HR
(BPM) — continuous heart rate trend, %Bad — the percentage of bad beats, defined as those more than 10%
premature or with correlation coefficient < 0.9, Noise [µV] — the mean noise in the vector magnitude (VM), Resp —
the measure of the respiration at the frequency of 0.25 cycles per beat, HR Delta — the measure of the difference
between the highest and lowest instantaneous heart rate in a 128 beat interval, RR Alternans — the alternans level in
the RR interval, expressed in milliseconds [ms], Onset HR — the lowest heart rate at which sustained alternans is
present, Max Neg HR — the highest interval HR of all intervals having no significant alternans or artefact.
Figure 2. Reproducibility of microvolt T-wave alternans (MTWA) in vector leads; VM — vector magnitude; X, Y, Z — Frank
leads, HR (BPM) — continuous heart rate trend, %Bad — the percentage of bad beats, defined as those more than
10% premature or with correlation coefficient < 0.9, Noise [µV] — the mean noise in the vector magnitude (VM),
Resp — the measure of the respiration at the frequency of 0.25 cycles per beat, HR Delta — the measure of the
difference between the highest and lowest instantaneous heart rate in a 128 beat interval, RR Alternans — the alternans
level in the RR interval, expressed in milliseconds [ms], Onset HR — the lowest heart rate at which sustained alternans
is present, Max Neg HR — the highest interval HR of all intervals having no significant alternans or artefact.
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period of the disease. Klingenheben et al. [24] also
tested the reproducibility of TWA over a long peri-
od, but their group of patients were early after
myocardial infarction. The reproducibility was 58%
of all and 82% of determinate results. The weaker
reproducibility for all the results was probably due
to the shift from indeterminate to determinate tests
in the unstable early phase of myocardial infarction
(8 ± 6 days after) compared to one year of follow-
up. Now it is recommended that T-wave alternans
tests be performed at least 6 weeks after the acute
phase of myocardial infarction [21, 22], which is
concordant with guidelines to implant the ICD not
earlier than 40 days after myocardial infarction.
Reproducibility in a short period, which means
immediate reproducibility, has also been the aim
of several other studies which have shown 82%
and 93% reproducibility for determine results in
Bloomfield et al. [23] and Turitto et al. [27] groups,
respectively. However, reproducibility of the re-
sults of the short period was outside our field of
interest. We were obliged to obtain determinate
results, so we had to repeat the test only when the
initial result had been indeterminate. When the
second test was indeterminate, mainly due to in-
sufficient heart rate or for other reasons such as
ventricular arrhythmia [25], we considered it as
a final result.
However, the determinate results are the most
important for risk stratification, and we would like
to stress that in this analysis we have shown the
reproducibility of an electrocardiographic pattern
— the alternans and the overall result of this. We
reached 73.6% reproducibility for determinate re-
sults, so the score was very similar to the repro-
ducibility for all the results. This means that the
pattern called alternans is reproducible and inde-
pendent under the stable conditions of the exami-
nation, even if the results are indeterminate. On the
other hand, there is increasing information that in-
determinate results should be treated as positive.
Therefore, if we assume that indeterminate results
are equal to positive ones, we could obtain much
better results of reproducibility.
We obtained a high percentage of indeterminate
results mainly due to insufficient heart rate, which
in turn was caused by beta-blocker treatment. We
could say that if we use beta-blockers, and if even it
does change the TWA appearance and we received
indeterminate results, it should be put into one group
together with the positive results, as non-negative
TWA. We now also know that even if beta-blockers
decrease the appearance of MTWA, when determin-
ing cardiovascular factors in high-risk patients, it is
recommended that T-wave alternans be performed
on beta-blockers [28–30].
We have also shown that onset HR is stable
with time. Turitto et al. [27] has shown in her study
that not only the onset HR is stable when T-wave
alternans is appearing, but also the magnitude of
TWA (the amplitude) and the number of leads show-
ing T-wave alternans is unchangeable.
Finally, we would like to stress that the clini-
cal status of our patients was stable during the fol-
low-up period. The reason we concluded this, as
well as careful investigation, is that we did not no-
tice differences between such parameters of ECG
as duration of QRS complex and duration of correct-
ed QT interval. Ejection fraction was unchangea-
ble during follow up as well.
On the basis of our results and references, we
would like to draw an algorithm of the performance
and timing of T-wave alternans measurement:
1. It should be performed during stable status of the
disease, at least six weeks after myocardial infarction;
2. It should be done during exercise testing to re-
ceive determinate results. If the result is indetermi-
nate, it is necessary to repeat it immediately. Atrial
pacing protocol as a priority or atrioventricular pac-
ing could be used if available; 3. It is not recommend-
ed to repeat the TWA testing after a longer period if
the status of the disease of the patient is unchanged.
Table 3. Clinical parameters.
Parameter Initial Second P
test  test
Onset HR 92.35 ± 10.02 94.61 ± 8.90 0.422
[beats/min]
HR 62.96 ± 8.84 65.58 ± 12.39 0.024
[beats/min]
QRS [ms] 125.33 ± 36.45 127.51 ± 37.43 0.607
QTc [ms] 457.06 ± 35.14 448.24 ± 48.62 0.133
EF (%) 34.70 ± 10.07 35.07 ± 8.11 0.281
Onset HR — the lowest heart rate at which sustained alternans is
present, HR — supine heart rate, QRS — time of QRS complex
duration, QTc — corrected QT interval, EF — ejection fraction
Table 2. Reproducibility of microvolt T-wave
alternans.
Initial test         Second test
Positive Negative Indeterminate
Positive 12 1 4
Negative 0 2 0
Indeterminate 1 1 9
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Conclusions
The results suggest that microvolt T-wave
alternans measurement is stable over long periods.
This means that the presence and absence of
MTWA is reliable. It is probably not worth repeat-
ing the test after several months to examine the
status of MTWA of the patients, at least if they are
in the chronic stage of their disease.
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